“A new non-opioid analgesic therapeutic class for acute pain offers an opportunity to mitigate certain risks associated with using an opioid for pain and provides patients with another treatment ...

Acute pain is often managed with analgesics that may or may not ... She noted that a new non-opioid therapeutic class for acute pain can help reduce certain risks associated with using opioids ...

“A new non-opioid analgesic therapeutic class for acute pain offers an opportunity to mitigate certain risks associated with using an opioid for pain and provides patients with another treatment ...

The U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine) oral tablets on Thursday as a first-in-class non-opioid analgesic to treat acute pain in adults. “Today’s approval ...

“A new non-opioid analgesic therapeutic class for acute pain offers an opportunity to mitigate certain risks associated with using an opioid for pain and provides patients with another treatment ...

“A new non-opioid analgesic therapeutic class for acute pain offers an opportunity to mitigate certain risks associated with using an opioid for pain and provides patients with another treatment ...

Suzetrigine is the first non-opioid analgesic – or medication to control pain – of its class to receive federal approval in more than 20 years. Vertex Pharmaceuticals claimed in a press ...

“A new non-opioid analgesic therapeutic class for acute pain offers an opportunity to mitigate certain risks associated with using an opioid for pain and provides patients with another treatment ...

A non-opioid pain medication made by Vertex Pharmaceuticals has received approval for adults from the Food and Drug Administration (FDA). The company’s "first-in-class" suzetrigine pain pill ...

Vertex Pharmaceuticals has scored an FDA approval for Journavx (suzetrigine), a non-opioid pain reliever that could usher in a new era of nonaddictive therapy in the indication. As an oral voltage ...